Grace Therapeutics, Inc.(GRCE)Earnings, Financials & Key Ratios
GRCE•NASDAQ
$2.37
$37M mkt cap·Price updated May 6, 2026
AboutGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.Show more
- Revenue$0
- EBITDA-$17M-47.5%
- Net Income-$10M+25.6%
- EPS (Diluted)-0.79+54.3%
- ROE-14.91%+24.8%
- ROIC-30.06%-40.5%
GRCE Key Insights
Grace Therapeutics, Inc. (GRCE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Shares diluted 62.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GRCE Price & Volume
Grace Therapeutics, Inc. (GRCE) stock price & volume — 10-year historical chart
Loading chart...
GRCE Growth Metrics
Grace Therapeutics, Inc. (GRCE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM55.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM70.68%
Return on Capital
10 Years-62.01%
5 Years-30.11%
3 Years-30.26%
Last Year-23.54%
GRCE Peer Comparison
Grace Therapeutics, Inc. (GRCE) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare GRCE vs Peers
Grace Therapeutics, Inc. (GRCE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GRCE Income Statement
Grace Therapeutics, Inc. (GRCE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Feb'16 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 27.79K | 0 | 0 | 0 | 196K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -87.15% | -100% | - | - | - | -100% | - | - | - | - |
| Cost of Goods Sold | 60.08K | 0 | 0 | 0 | 76K | 0 | 0 | 11K | 0 | 2K |
| COGS % of Revenue | 216.22% | - | - | - | 38.78% | - | - | - | - | - |
| Gross Profit | -32.29K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 120K▲ 0% | 0▼ 100.0% | 0▲ 0% | -11K▲ 0% | 0▲ 100.0% | -2K▲ 0% |
| Gross Margin % | -116.22% | - | - | - | 61.22% | - | - | - | - | - |
| Gross Profit Growth % | -213.74% | 100% | - | - | - | -100% | - | - | 100% | - |
| Operating Expenses | 7.03M | 15.25M | 34.41M | 24.44M | 16.54M | 15.59M | 52.16M | 11.3M | 16.68M | 11.25M |
| OpEx % of Revenue | 25310.4% | - | - | - | 8438.27% | - | - | - | - | - |
| Selling, General & Admin | 1.51M | 3.12M | 4.29M | 8.46M | 6.66M | 9.78M | 8.21M | 6.67M | 7.16M | 7.63M |
| SG&A % of Revenue | 5434.2% | - | - | - | 3395.41% | - | - | - | - | - |
| Research & Development | 5.58M | 12.13M | 29.37M | 15.97M | 4.17M | 5.56M | 9.97M | 4.63M | 9.51M | 3.62M |
| R&D % of Revenue | 20092.13% | - | - | - | 2129.08% | - | - | - | - | - |
| Other Operating Expenses | -60.08K | 0 | 741K | 0 | 5.71M | 249K | 33.97M | 0 | 7K | 2K |
| Operating Income | -7.09M▲ 0% | -15.25M▼ 115.0% | -34.41M▼ 125.6% | -24.44M▲ 29.0% | -16.42M▲ 32.8% | -15.59M▲ 5.1% | -52.16M▼ 234.6% | -11.31M▲ 78.3% | -16.68M▼ 47.4% | -8.8M▲ 0% |
| Operating Margin % | -25526.33% | - | - | - | -8377.04% | - | - | - | - | - |
| Operating Income Growth % | 28.4% | -115.03% | -125.58% | 28.97% | 32.81% | 5.06% | -234.56% | 78.31% | -47.45% | - |
| EBITDA | -5.33M | -13.18M | -32.07M | -22.12M | -15.49M | -15.34M | -52.03M | -11.3M | -16.67M | -8.8M |
| EBITDA Margin % | -19167.24% | - | - | - | -7905.61% | - | - | - | - | - |
| EBITDA Growth % | 33.76% | -147.52% | -143.29% | 31.04% | 29.94% | 1% | -239.19% | 78.28% | -47.53% | 47.5% |
| D&A (Non-Cash Add-back) | 1.77M | 2.07M | 2.33M | 2.32M | 924K | 0 | 124K | 11K | 7K | 5K |
| EBIT | -4.66M | -16.37M | -39.09M | -25.27M | -10.72M | -15.34M | -18.25M | -14.63M | -16.68M | -4.41M |
| Net Interest Income | 52.39K | -1.11M | -427K | 43K | -157K | 77K | 246K | 911K | 711K | 544K |
| Interest Income | 53.87K | 55.75K | 358K | 336K | 107K | 77K | 246K | 911K | 711K | 544K |
| Interest Expense | 1.48K | 283.41K | 278K | 293K | 264K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.43M | -1.4M | -4.96M | -1.07M | -3.26M | 5.12M | 184K | -3.32M | 3.91M | 4.12M |
| Pretax Income | -4.66M▲ 0% | -16.65M▼ 257.2% | -39.37M▼ 136.4% | -25.51M▲ 35.2% | -19.68M▲ 22.9% | -10.47M▲ 46.8% | -51.97M▼ 396.5% | -14.63M▲ 71.8% | -12.77M▲ 12.7% | -7M▲ 0% |
| Pretax Margin % | -16777.63% | - | - | - | -10039.8% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -648K | -9.54M | -1.78M | -3.2M | -1.02M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 6.19% | 18.36% | 12.15% | 25.06% | 14.55% |
| Net Income | -4.66M▲ 0% | -16.65M▼ 257.2% | -39.37M▼ 136.4% | -25.51M▲ 35.2% | -19.68M▲ 22.9% | -9.82M▲ 50.1% | -42.43M▼ 332.1% | -12.85M▲ 69.7% | -9.57M▲ 25.6% | -5.98M▲ 0% |
| Net Margin % | -16777.63% | - | - | - | -10039.8% | - | - | - | - | - |
| Net Income Growth % | -252.38% | -257.19% | -136.4% | 35.19% | 22.87% | 50.1% | -332.11% | 69.71% | 25.56% | 55.28% |
| Net Income (Continuing) | -4.66M | -16.65M | -39.37M | -25.51M | -19.68M | -9.82M | -42.43M | -12.85M | -9.57M | -3.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -27.94▲ 0% | -58.96▼ 111.0% | -46.90▲ 20.5% | -14.40▲ 69.3% | -7.98▲ 44.6% | -1.60▲ 79.9% | -5.71▼ 256.9% | -1.73▲ 69.7% | -0.79▲ 54.3% | -0.35▲ 0% |
| EPS Growth % | -191.35% | -111.02% | 20.45% | 69.3% | 44.58% | 79.95% | -256.88% | 69.7% | 54.34% | 70.68% |
| EPS (Basic) | -27.94 | -58.96 | -46.90 | -14.40 | -7.98 | -1.60 | -5.71 | -1.73 | -0.79 | - |
| Diluted Shares Outstanding | 222.08K | 364.3K | 1.13M | 1.76M | 2.47M | 6.14M | 7.43M | 7.44M | 12.09M | 16.93M |
| Basic Shares Outstanding | 222.08K | 364.3K | 1.13M | 1.76M | 2.47M | 6.14M | 7.43M | 7.44M | 12.09M | 16.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GRCE Balance Sheet
Grace Therapeutics, Inc. (GRCE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Feb'16 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.36M | 7.35M | 27.97M | 15.96M | 62.37M | 45.53M | 29.29M | 24.01M | 22.71M | 19.21M |
| Cash & Short-Term Investments | 7.73M | 6.37M | 25.76M | 14.24M | 60.73M | 43.66M | 27.89M | 23M | 22.13M | 18.67M |
| Cash Only | 2.23M | 6.37M | 16.87M | 14.24M | 50.94M | 30.34M | 27.88M | 23M | 22.13M | 18.67M |
| Short-Term Investments | 5.49M | 0 | 8.89M | 0 | 9.79M | 13.32M | 15K | 0 | 0 | 0 |
| Accounts Receivable | 294.44K | 587.73K | 1.19M | 546K | 530K | 548K | 802K | 722K | 126K | 20K |
| Days Sales Outstanding | 3.87K | - | - | - | 986.99 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 80.53K | 183K | 195K | 768K | 602K | 0 | 0 | 0 | 519K |
| Total Non-Current Assets | 12.69M | 10.43M | 8.93M | 6.89M | 86K | 83.09M | 49.83M | 49.29M | 49.28M | 49.28M |
| Property, Plant & Equipment | 211.79K | 2.18M | 2.11M | 2.06M | 86K | 315K | 567K | 24K | 15K | 0 |
| Fixed Asset Turnover | 0.13x | - | - | - | 2.28x | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 12.96M | 8.14M | 8.14M | 8.14M | 8.14M |
| Intangible Assets | 11M | 7.79M | 6.39M | 4.24M | 0 | 69.81M | 41.13M | 41.13M | 41.13M | 41.13M |
| Long-Term Investments | 0 | 20.13K | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.48M | 429.76K | 417K | 594K | 0 | 0 | 0 | 0 | 0 | 11K |
| Total Assets | 21.04M▲ 0% | 17.78M▼ 15.5% | 36.9M▲ 107.5% | 22.85M▼ 38.1% | 62.46M▲ 173.3% | 128.62M▲ 105.9% | 79.12M▼ 38.5% | 73.3M▼ 7.4% | 71.99M▼ 1.8% | 68.49M▲ 0% |
| Asset Turnover | 0.00x | - | - | - | 0.00x | - | - | - | - | 0.00x |
| Asset Growth % | -29.24% | -15.52% | 107.53% | -38.06% | 173.3% | 105.93% | -38.48% | -7.36% | -1.78% | 12.08% |
| Total Current Liabilities | 842K | 5.19M | 13.67M | 7.39M | 1.58M | 3.26M | 3.41M | 1.68M | 1.93M | 1.28M |
| Accounts Payable | 276.73K | 2.65M | 3.05M | 1.71M | 115K | 3.16M | 1.24M | 1.01M | 601K | 0 |
| Days Payables Outstanding | 1.68K | - | - | - | 552.3 | - | - | 33.41K | - | 117.72K |
| Short-Term Debt | 0 | 0 | 1.36M | 76K | 86K | 104K | 75K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 2.81M | 607K | 0 | 946K | 0 | 0 | 1.28M |
| Current Ratio | 9.93x | 1.42x | 2.05x | 2.16x | 39.50x | 13.97x | 8.59x | 14.26x | 11.77x | 11.77x |
| Quick Ratio | 9.93x | 1.42x | 2.05x | 2.16x | 39.50x | 13.97x | 8.59x | 14.26x | 11.77x | 11.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 115.12K | 6.22M | 12.18M | 2.46M | 5.22M | 17.09M | 7.76M | 9.87M | 3.45M | 2.31M |
| Long-Term Debt | 0 | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 71K | 0 | 191K | 410K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 16.89M | 7.35M | 5.51M | 2.31M | 9.25M |
| Other Non-Current Liabilities | 115.12K | 4.98M | 12.18M | 2.39M | 5.22M | 10K | 0 | 4.36M | 1.14M | 2.97M |
| Total Liabilities | 957.12K | 11.41M | 25.85M | 9.86M | 6.8M | 20.35M | 11.17M | 11.56M | 5.38M | 3.6M |
| Total Debt | 0 | 1.25M | 1.36M | 147K | 86K | 295K | 485K | 0 | 0 | 0 |
| Net Debt | -2.23M | -5.12M | -15.51M | -14.09M | -50.86M | -30.04M | -27.39M | -23M | -22.13M | -18.67M |
| Debt / Equity | - | 0.20x | 0.12x | 0.01x | 0.00x | 0.00x | 0.01x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.12x |
| Interest Coverage | -4805.56x | -53.82x | -123.76x | -83.41x | -62.19x | - | - | - | - | - |
| Total Equity | 20.09M▲ 0% | 6.37M▼ 68.3% | 11.04M▲ 73.4% | 12.99M▲ 17.6% | 55.66M▲ 328.4% | 108.27M▲ 94.5% | 67.95M▼ 37.2% | 61.74M▼ 9.1% | 66.61M▲ 7.9% | 64.89M▲ 0% |
| Equity Growth % | -24.37% | -68.3% | 73.44% | 17.65% | 328.35% | 94.52% | -37.24% | -9.14% | 7.88% | 51.3% |
| Book Value per Share | 90.45 | 17.48 | 9.77 | 7.37 | 22.53 | 17.63 | 9.14 | 8.30 | 5.51 | 3.83 |
| Total Shareholders' Equity | 20.09M | 6.37M | 11.04M | 12.99M | 55.66M | 108.27M | 67.95M | 61.74M | 66.61M | 64.89M |
| Common Stock | 45.73M | 56.79M | 110.86M | 137.42M | 197.19M | 257.99M | 258.29M | 261.04M | 1K | 1K |
| Retained Earnings | -29.24M | -56.05M | -100.83M | -126.34M | -146.02M | -155.84M | -198.27M | -211.12M | -220.69M | -227.3M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -7.89M | -6.33M | -6.04M | -6.04M | -6.04M | -6.04M | -6.04M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GRCE Cash Flow Statement
Grace Therapeutics, Inc. (GRCE) cash flow — operating, investing & free cash flow history
| Line item | Feb'16 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.85M | -9.69M | -24.79M | -22.95M | -14.32M | -17.23M | -15.91M | -12.33M | -14.9M | -14.9M |
| Operating CF Margin % | -17458.76% | - | - | - | -7305.61% | - | - | - | - | - |
| Operating CF Growth % | 15.67% | -99.83% | -155.69% | 7.41% | 37.61% | -20.36% | 7.67% | 22.5% | -20.85% | 80.11% |
| Net Income | -4.66M | -16.65M | -39.37M | -25.51M | -19.68M | -9.82M | -42.43M | -12.85M | -9.57M | -5.98M |
| Depreciation & Amortization | 1.77M | 2.07M | 2.33M | 2.32M | 924K | 0 | 124K | 11K | 7K | 7K |
| Stock-Based Compensation | 228.03K | 719.37K | 777K | 1.95M | 1.17M | 1.34M | 1.81M | 913K | 730K | 746K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -648K | -9.54M | -1.83M | -3.2M | -1.02M |
| Other Non-Cash Items | -2.15M | 1.39M | 5.28M | 1.51M | 9.21M | -5.32M | 33.94M | 2.71M | -3.22M | -3.82M |
| Working Capital Changes | -30.25K | 2.77M | 6.19M | -3.22M | -5.95M | -2.79M | 181K | -1.28M | 342K | -66K |
| Change in Receivables | 336.5K | -428.21K | -620K | 581K | 58K | -18K | -302K | 80K | 596K | 281K |
| Change in Inventory | 64.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 36.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 6.07M | -318.26K | -9.44M | 8.14M | -9.86M | -3.52M | 13.15M | 104K | 0 | 0 |
| Capital Expenditures | -203.67K | -352.33K | -534K | -319K | -69K | 0 | -17K | -22K | 0 | 0 |
| CapEx % of Revenue | 732.98% | - | - | - | 35.2% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 16.23K | 54.2K | 0 | 0 | 0 | 0 | 0 | 111K | 0 | 0 |
| Cash from Financing | -2.21K | 8.83M | 45.69M | 13.18M | 59.49M | 0 | 304K | 7.36M | 14.03M | 17.75M |
| Debt Issued (Net) | 0 | 0 | 0 | -1.56M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 0 | 304K | 1000K | 1000K | 999.23K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -30.97K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -2.21K | 295.03K | 798K | 7.76M | 158K | 0 | 0 | -141K | -967K | 2.75M |
| Net Change in Cash | 1.27M▲ 0% | -1.2M▼ 194.7% | 10.45M▲ 971.1% | -2.63M▼ 125.2% | 36.7M▲ 1495.0% | -20.6M▼ 156.1% | -2.46M▲ 88.0% | -4.87M▼ 97.6% | -872K▲ 82.1% | 7.62M▲ 0% |
| Free Cash Flow | -5.12M▲ 0% | -10.05M▼ 96.1% | -25.32M▼ 152.0% | -23.27M▲ 8.1% | -14.39M▲ 38.2% | -17.23M▼ 19.8% | -15.93M▲ 7.6% | -12.36M▲ 22.4% | -14.9M▼ 20.6% | -10.13M▲ 0% |
| FCF Margin % | -18436.07% | - | - | - | -7340.82% | - | - | - | - | - |
| FCF Growth % | 12.01% | -96.11% | -152.04% | 8.1% | 38.17% | -19.78% | 7.57% | 22.44% | -20.63% | 27.97% |
| FCF per Share | -23.07 | -27.58 | -22.39 | -13.21 | -5.82 | -2.81 | -2.14 | -1.66 | -1.23 | -1.23 |
| FCF Conversion (FCF/Net Income) | 1.04x | 0.58x | 0.63x | 0.90x | 0.73x | 1.76x | 0.38x | 0.96x | 1.56x | 1.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GRCE Key Ratios
Grace Therapeutics, Inc. (GRCE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -19.99% | -125.89% | -452.14% | -212.26% | -57.33% | -11.98% | -48.15% | -19.82% | -14.91% | -9.21% |
| Return on Invested Capital (ROIC) | -24.54% | -119.77% | - | - | -664.74% | -28.16% | -65.86% | -21.4% | -30.06% | -30.06% |
| Gross Margin | -116.22% | - | - | - | 61.22% | - | - | - | - | - |
| Net Margin | -16777.63% | - | - | - | -10039.8% | - | - | - | - | - |
| Debt / Equity | - | 0.20x | 0.12x | 0.01x | 0.00x | 0.00x | 0.01x | - | - | 0.00x |
| Interest Coverage | -4805.56x | -53.82x | -123.76x | -83.41x | -62.19x | - | - | - | - | - |
| FCF Conversion | 1.04x | 0.58x | 0.63x | 0.90x | 0.73x | 1.76x | 0.38x | 0.96x | 1.56x | 1.69x |
| Revenue Growth | -87.15% | -100% | - | - | - | -100% | - | - | - | - |
GRCE Frequently Asked Questions
Grace Therapeutics, Inc. (GRCE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Grace Therapeutics, Inc. (GRCE) grew revenue by 0.0% over the past year. Growth has been modest.
Grace Therapeutics, Inc. (GRCE) reported a net loss of $6.0M for fiscal year 2025.
Dividend & Returns
Grace Therapeutics, Inc. (GRCE) has a return on equity (ROE) of -14.9%. Negative ROE indicates the company is unprofitable.
Grace Therapeutics, Inc. (GRCE) had negative free cash flow of $10.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More GRCE
Grace Therapeutics, Inc. (GRCE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates